On covers of cyclic acts over monoids

In (Bull. Lond. Math. Soc. 33:385–390, 2001) Bican, Bashir and Enochs finally solved a long standing conjecture in module theory that all modules over a unitary ring have a flat cover. The only substantial work on covers of acts over monoids seems to be that of Isbell (Semigroup Forum 2:95–118, 1971), Fountain (Proc. Edinb. Math. Soc. (2) 20:87–93, 1976) and Kilp (Semigroup Forum 53:225–229, 1996) who only consider projective covers. To our knowledge the situation for flat covers of acts has not been addressed and this paper is an attempt to initiate such a study. We consider almost exclusively covers of cyclic acts and restrict our attention to strongly flat and condition (P) covers. We give a necessary and sufficient condition for the existence of such covers and for a monoid to have the property that all its cyclic right acts have a strongly flat cover (resp. (P)-cover). We give numerous classes of monoids that satisfy these conditions and we also show that there are monoids that do not satisfy this condition in the strongly flat case. We give a new necessary and sufficient condition for a cyclic act to have a projective cover and provide a new proof of one of Isbell’s classic results concerning projective covers. We show also that condition (P) covers are not unique, unlike the situation for projective covers

Comparison of CDMA and FDMA for the MobileStar(sm) system

Spread-spectrum code division multiple access (CDMA) and single channel per carrier frequency division multiple access (FDMA) systems are compared for spectrum efficiency. CDMA is shown to have greater maximum throughput than FDMA for the MobileStar(sm) system which uses digital voice activated carriers and directive circularly polarized satellite antennas

Differential Effects of Mindful Breathing and Loving Kindness Meditations: A Component Analysis Study

Objective: Mindful breathing meditation (MBM) and loving-kindness meditation (LKM) are common components of effective mindfulness-based interventions (MBIs). This study examined the differential effects of MBM and LKM on purported therapeutic process variables and mental health outcomes via component analysis. Method: The research design was a randomized controlled trial with four conditions: MBM, LKM, combined (MBM + LKM), and a relaxation control. All conditions consisted of 10-min. audio-recorded guided meditations that were self-implemented over the course of two weeks. Participants were college undergraduates (N = 52). Results: Findings indicated statistically significant and very large main effects of time, regardless of condition. Statistically significant time by condition interactions were only observed for one process variable (i.e., defusion) and one mental health outcome (i.e., depression). Follow-up descriptive evaluation of between-group effect sizes indicated patterns of favorable effects for MBM and LKM over the combined and relaxation control conditions. Treatment integrity and treatment acceptability data indicated very favorable social validity across conditions. Discussion: We conclude that our findings make a modest yet value-added contribution to the MBI component analysis literature, suggesting differentiated performance among isolated MBM and LKM exercises compared to combined and control conditions. Yet further research is warranted to improve upon the limitations of this study

Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance? A Pilot Assessment

SWI/SNF chromatin-modification complexes use the energy of ATP hydrolysis to remodel nucleosomes and to affect transcription and several cellular processes. Accordingly, their loss of function has been associated with malignant transformation. ARID1A (the expression of whose product, BAF250a, a key complex component, is lost when mutated) has recently been identified as a tumor suppressor gene that is mutated in 46-57% of ovarian clear cell carcinoma (CCC). The purposes of this study are to assess the frequency of loss of BAF250a expression in endometrial CCC and whether this loss has any discernable clinicopathologic implications. 34 endometrial carcinomas with a CCC component (including 22 pure CCC, 8 mixed carcinomas with a 10% CCC component, and 4 carcinosarcomas with a CCC epithelial component), were evaluated by immunohistochemistry using a monoclonal antibody directed against the human BAF250a protein. 5 (22.7%) of the 22 pure CCC were entirely BAF250a negative, whereas the remainder showed diffuse immunoreactivity. None of 4 carcinosarcomas and only 1 (12.5%) of the 8 mixed carcinomas were BAF250a negative. There was no discernable relationship between BAF250a immunoreactivity status and tumor architectural patterns (solid, papillary or tubulocystic areas) or cell type (flat, hobnail or polygonal). Of the 22 patients with pure CCC, 14, 2, 3, and 3 were International Federation of Gynecology and Obstetrics stages 1, II, III and IV respectively. Interestingly, all 5 BAF250a negative cases were late stage [stages III or IV] as compared with 1 of 17 BAF250a positive cases (p=0.0002). Thus, 83% (5/6) of all late stage cases were BAF250a [-], as compared with 0 (0%) of the 16 early stage (I or II) cases (p=.0002). BAF250a negative and positive cases did not show any statistically significant difference regarding patient age and frequency of lymphovascular invasion or myometrial invasion. As may be anticipated from the concentration of late stage cases in the BAF250a negative group, patient outcomes were worsened in that group on univariate analysis. In conclusion, we found in this pilot assessment that 22.7% of endometrial CCC displays complete loss of BAF250a expression. There was a disproportionate concentration of BAF250a negative cases in the late stage group, with the attendant possibility of an associated worsened prognosis for those CCC patients whose tumors are BAF250a negative. These preliminary findings suggest the need for larger analyses to evaluate the prognostic significance, if any, of the loss of BAF250a expression in this rare histotype of endometrial cancer

Co-Administration of Iron and Bioavailable Curcumin Reduces Levels of Systemic Markers of Inflammation and Oxidative Stress in a Placebo-Controlled Randomised Study

Ferrous sulphate (FS) is widely used as an iron supplement to treat iron deficiency (ID), but is known to induce inflammation causing gastric side-effects resulting in poor adherence to supplement regimens. Curcumin, a potent antioxidant, has been reported to suppress inflammation via down regulation of NF-κB. The aim of the present double blind, placebo-controlled randomised trial was to assess whether co-administration of FS with a formulated, bioavailable form of curcumin (HydroCurc™) could reduce systemic inflammation and/or gastrointestinal side-effects. This study recruited 155 healthy participants (79 males; 26.42 years ± 0.55 and 76 females; 25.82 years ± 0.54), randomly allocated to one of five different treatment groups: iron and curcumin placebo (FS0_Plac), low dose (18 mg) iron and curcumin placebo (FS18_Plac), low dose iron and curcumin (FS18_Curc), high dose (65 mg) iron and curcumin placebo (FS65_Plac), and high dose iron and curcumin (FS65_Curc). Completed questionnaires and blood samples were collected from all participants at baseline (day 1), mid-point (day 21), and at end-point (day 42). Results showed a significant reduction in IL-6 in the FS65_Curc group (0.06 pg/mL ± 0.02, p = 0.0073) between the mid-point and end-point. There was also a significant reduction in mean plasma TNF levels in the FS65_Curc (0.65 pg/mL ± 0.17, p = 0.0018), FS65_Plac (0.39 pg/mL ± 0.15, p = 0.0363), and FS18_Curc (0.35 pg/mL ± 0.13, p = 0.0288) groups from mid-point to end-point. A significant increase was observed in mean plasma TBARS levels (0.10 µM ± 0.04, p = 0.0283) in the F18_Plac group from baseline to end-point. There was a significant association with darker stools between FS0_Plac vs. FS65_Plac (p = 0.002, Fisher’s exact test) suggesting that high iron dose in the absence of curcumin leads to darker stools. A reduction in inflammation-related markers in response to co-administering supplemental iron alongside formulated curcumin suggests a reduction in systemic inflammation. This supplementation approach may therefore be a more cost effective and convenient alternative to current oral iron-related treatments, with further research to be conducted

Using content language analysis system indexes (CLASI) in the development of English testing materials

Articl

Social Judgement, the Semantic Differential, and Attitude Intensity

The basic problem of this study Is whether or not the semantic differential attitude instrument may be used to measure attitude Intensity. The method of determining this is to use an instrument which is known to measure attitude Intensity in conjunction with the semantic differential and determine whether or not a significant correlation exists between the two

Co-Administration of Iron and a Bioavailable Curcumin Supplement Increases Serum BDNF Levels in Healthy Adults

Brain-derived neurotrophic factor (BDNF) is key for the maintenance of normal neuronal function and energy homeostasis and has been suggested to improve cognitive function, including learning and memory. Iron and the antioxidant curcumin have been shown to influence BDNF homeostasis. This 6-week, double blind, randomized, placebo-controlled study examined the effects of oral iron supplementation at low (18 mg) and high (65 mg) ferrous (FS) iron dosages, compared to a combination of these iron doses with a bioavailable formulated form of curcumin (HydroCurcTM; 500 mg) on BDNF levels in a healthy adult cohort of 155 male (26.42 years ± 0.55) and female (25.82 years ± 0.54) participants. Participants were randomly allocated to five different treatment groups: both iron and curcumin placebo (FS0+Plac), low dose iron and curcumin placebo (FS18+Plac), low dose iron and curcumin (FS18+Curc), high dose iron and curcumin placebo (FS65+Plac) and high dose iron and curcumin (FS65+Curc). Results showed a significant increase in BDNF over time (26%) in the FS18+Curc group (p = 0.024), and at end-point between FS18+Curc and FS18+Plac groups (35%, p = 0.042), demonstrating for the first time that the combination with curcumin, rather than iron supplementation alone, results in increased serum BDNF. The addition of curcumin to iron supplementation may therefore provide a novel approach to further enhance the benefits associated with increased BDNF levels

Operando magnetic resonance studies of phase behaviour and oligomer accumulation within catalyst pores during heterogeneous catalytic ethene oligomerization

Two-dimensional 1H magnetic resonance imaging and spatially-resolved 1H magnetic resonance spectroscopy and diffusion measurements were recorded as a function of time-on-stream within a fixed-bed reactor to provide direct measurements of the progress of the heterogeneous catalytic oligomerization of ethene occurring over a 1 wt% Ni-Al2O3-SiO2 catalyst. The catalyst bed was of internal diameter 2 cm; magnetic resonance measurements were recorded over a bed length of 5.5 cm. Experiments were conducted at a temperature and pressure of 110 °C and 29 bara, respectively, with continuous downflow of ethene at a flowrate of 0.78 L h-1. During conversion the accumulation of 1H-containing species within the catalyst pellets was imaged, and spatially-resolved 1H NMR spectra were recorded at 1 mm intervals along the length of the reactor. Diffusion-filtered 1D chemical shift imaging was used to discriminate between gas- and liquid-phase species along the length of the reactor at 1 mm intervals. Finally, spectrally-encoded pulsed field gradient measurements of molecular diffusion were employed to infer the molecular composition of the gas and liquid phases and to identify populations of these phases inside and external to the pore space of the catalyst pellets; these measurements were spatially-resolved along the length of the reactor, with data being averaged over sections of height 4 mm. The results are consistent with oligomers of carbon number C20 and greater existing within the pores of the catalyst pellets which act to block the pore space, thereby deactivating the catalyst